S&P 500
5,935.94
+0.4%
+$24.25
DJI
42,305.48
+0.1%
+$35.41
NASDAQ
19,242.61
+0.7%
+$128.85
Bitcoin
105,255.00
+0.5%
+555.74
AAPL
$201.68
+0.4%
+$0.83
AMZN
$206.65
+0.8%
+$1.64
GOOG
$170.36
-1.4%
-$2.49
META
$670.89
+3.6%
+$23.40
MSFT
$461.42
+0.2%
+$1.06
NVDA
$137.42
+1.7%
+$2.28
TSLA
$342.54
-1.1%
-$3.92
Cheryl Swanson
CherylSwanson
Cheryl has six books published, and currently resides in Hawaii with her husband, her daughter and two dozen surfboards. With a 20-year background as a former medical technology and management consultant, as well as a cancer survivor, Cheryl has a unique perspective on health care. Follow her on Twitter at @uthorcdswanson
Recent Articles by Cheryl Swanson
Sep 13, 2015
by Cheryl Swanson, Todd Campbell, and George Budwell
These Clinical-Stage Biotechs Could Be Ripe for a Takeover
In the binary world of small biotechs, M&A activity can move share price even faster than clinical data. Just recognize that M&A speculation is exactly that -- speculation, not investing.
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.